bachelorThesis
Frecuencia de trombofilias en una población de pacientes con episodios trombóticos en un hospital universitario de III nivel
Fecha
2011Registro en:
Dahlbäch B, Carlson M, Svenson P. Familial thrombophilia due to a previously
unrecognized mechanism characterized by poor anticoagulant response to activated
Protein C. Proc Natl Acad Sci 1993; 90: 1004.
Guidelines on the investigation and management of thrombophilia. J Clin Pathol
1990; 49: 703.
GRIFFIN V, SELIGSOH U, RAPPORT S. Coagulation abnormalities in thrombosis.
American Society Hematology. Educational Session. Bocklet, Seattle, Washington
1995; 51‐8.
CONRAD F. Thrombophilia: diagnosis and management. En: Poller L, Thomas JM
(eds): Thrombosis and its Management. London: Churchill‐Livingstone Inc 1993; 113‐
25.
. Bauer K, Goodnight S, Ridkes P. Hypercoagulable States‐Translation of Risk Factors to
Clinical Practice. The American Society of Hematology Education Program Book.
Janine Editor 1998; 255‐73.
Arnaud E, Reny J, Emmerich J, Aiach M. Thrombose veineusse et anomalies
genétiques de l’hémostase. Sang Thrombose et Vaissaux 2000; 7: 426‐32.
Heijboer H, Brandjes D, Büller H, Sturka A, Ten Cate J. Deficiencies of coagulation‐
inhibitingand fibrinolytic proteins in outpatients with deep venous thrombosis. N
Engl J Med 1990; 323: 1512‐6.
Hach‐Wunderle V, Scharrer I. Prevalence of hereditary deficiency of antithrombin III,
Protein C en Protein S. Dtsch Med Wochenschr 1993; 118: 187‐90.
Dahlbäch B. New molecular insights into the genetics of thrombophilia. Resistance to
activated protein C caused by Arg (506) to Gln mutation in factor V as a pathogenic
risk factor for venous thrombosis. Thromb Haemost 1995; 74: 139‐48.
Bertina RM, Reitsma PH, Rosendaal FR, Vandenbroucke JP. Resistance to activated
protein C and Factor V as risk factors for venous thrombosis. Thromb Haemost 1995;
74: 449‐53.
Mercier E, Queré I, Gris J‐C. Variant 20210 A dugène de la Prothrombine et
Thrombose. STV 2001; 4: 13‐23.
Grinsberg JS. Management of venous thromboembolism. N Engl J Med 1996; 335:
1816‐28.
Derksen Rh, De Groot Pg, Kater L, Nieuwenhuis Hk. Patients with antiphospholipid
antibodies and venous thrombosis should receive long term anticoagulant treatment.
Ann Rheum Dis 1993; 52: 689‐92.
Khamashta Ma, Cuadrado Mj, Mujic F, Taub Na, Hunt Bj, Hughes Gr. The
management of thrombosis in the antiphospholipid antibody syndrome. N Eng J Med
1995; 332: 993‐7
Torres, J. Inherited Thrombophilia is Associated With Deep Vein Thrombosis in a
Colombian Population. American Journal of Hematology 81:933–937 (2006).
Alfirevic, Z, Alfirevic, V. Hypercoagulable state, pathophysiology, classification and
epidemiology. Clin Chem Lab Med 2010;48(Suppl 1):S15–S26
. Stegnar, M. Thrombophilia screening – at the right time, for the right patient, with a
good reason. Clin Chem Lab Med 2010;48(Suppl 1):S105–S113 2010
Alfirevic, Z, Alfirevic, V. Hypercoagulable state, pathophysiology, classification and
epidemiology. Clin Chem Lab Med 2010;48(Suppl 1):S15–S26
. Olson ST, Björk I. Regulation of thrombin activity by antithrombin and heparin. Semin
Thromb Hemost 1994;20(4):373e409.
Anderson J, Witz J. Hypercoagulable States. Clin Chest Med 31 (2010) 659–673
Hirsh J, Bauer KA, Donati MB, et al. Parenteral anticoagulants: American College of
Chest Physicians Evidence‐Based Clinical Practice Guidelines (8th Edition). Chest
2008; 133:141S.
Martinelli I, Mannucci PM, De Stefano V, et al. Different risks of thrombosis in four
coagulation defects associated with inherited thrombophilia: a study of 150 families.
Blood 1998; 92:2353.
Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood
2007; 109:3161.
Tait RC, Walker ID, Reitsma PH, et al. Prevalence of protein C deficiency in the healthy
population. Thromb Haemost 1995; 73:87.
Bruijn SF, Stam J, Koopman MM, Vandenbroucke JP. Case‐control study of risk of
cerebral sinus thrombosis in oral contraceptive users and in [correction of who are]
carriers of hereditary prothrombotic conditions. The Cerebral Venous Sinus
Thrombosis Study Group. BMJ 1998; 316:589
Nazarian RM, Van Cott EM, Zembowicz A, Duncan LM. Warfarin‐induced skin
necrosis. J Am Acad Dermatol 2009; 61:325.
Rezende SM, Simmonds RE, Lane DA. Coagulation, inflammation, and apoptosis:
different roles for protein S and the protein S‐C4b binding protein complex. Blood
2004; 103:1192
Rezende SM, Simmonds RE, Lane DA. Coagulation, inflammation, and apoptosis:
different roles for protein S and the protein S‐C4b binding protein complex. Blood
2004; 103:1192.
Mustafa S, Mannhalter C, Rintelen C, et al. Clinical features of thrombophilia in
families with gene defects in protein C or protein S combined with factor V . Blood
Coagul Fibrinolysis 1998; 9:85.
Mateo J, Oliver A, Borrell M, et al. Laboratory evaluation and clinical characteristics of
2,132 consecutive unselected patients with venous thromboembolism‐‐results of the
Spanish Multicentric Study on Thrombophilia (EMET‐Study). Thromb Haemost 1997;
77:444.
Castoldi E, Brugge JM, Nicolaes GA, et al. Impaired APC cofactor activity of factor V
plays a major role in the APC resistance associated with the factor V Leiden (R506Q)
and R2 (H1299R) mutations. Blood 2004; 103:4173
Castoldi E, Rosing J. APC resistance: biological basis and acquired influences. J
Thromb Haemost 2010; 8:445.
Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the
3'‐untranslated region of the prothrombin gene is associated with elevated plasma
prothrombin levels and an increase in venous thrombosis. Blood 1996; 88:3698.
Rosendaal FR, Doggen CJ, Zivelin A, et al. Geographic distribution of the 20210 G to A
prothrombin variant. Thromb Haemost 1998; 79:706
O'Donnell J, Tuddenham EG, Manning R, et al. High prevalence of elevated factor VIII
levels in patients referred for thrombophilia screening: role of increased synthesis
and relationship to the acute phase reaction. Thromb Haemost 1997; 77:825.
Viel KR, Machiah DK, Warren DM, et al. A sequence variation scan of the coagulation
factor VIII (FVIII) structural gene and associations with plasma FVIII activity levels.
Blood 2007; 109:3713.
Lodi S, Isa L, Pollini E, et al. Defective intrinsic fibrinolytic activity in a patient with
severe factor XII‐deficiency and myocardial infarction. Scand J Haematol 1984; 33:80.
Goldhaber SZ. Risk factors for venous thromboembolism. J Am Coll Cardiol 2010;
56:1
Anderson J, Witz J. Hypercoagulable States. Clin Chest Med 31 (2010) 659–673
Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an
update of the classification criteria for definite antiphospholipid syndrome (APS). J
Thromb Haemost 2006; 4:295.
Geerts, W. Pineo,G. Prevention of Venous Thromboembolism. The Seventh ACCP
Conference on Antithrombotic and Thrombolytic Therapy
Kujovich JL. Hormones and pregnancy: thromboembolic risks for women. Br J
Haematol 2004; 126:443.
Spencer FA, Emery C, Lessard D, et al. The Worcester Venous Thromboembolism
study: a population‐based study of the clinical epidemiology of venous
thromboembolism. J Gen Intern Med 2006; 21:722.
Pomp ER, Rosendaal FR, Doggen CJ. Smoking increases the risk of venous thrombosis
and acts synergistically with oral contraceptive use. Am J Hematol 2008; 83:97
Ministerio de Salud .Resolución No. 008430 de 1993.
152679
TE00280
Autor
Feliciano Alfonso, John Edwin
Institución
Resumen
Las trombofilias se definen como tendencia a las trombosis, con variedad de manifestaciones clínicas. Se determinó la frecuencia de trombofilias en una población de pacientes con episodios trombóticos de la Consulta Externa de Hematología en un Hospital de III Nivel de Cundinamarca. Se incluyeron 94 pacientes, 70.2% presentó un evento trombótico, 16% presentó 2 eventos y 13.9% presentó 3 o más; en 47.9% pacientes se identifico alguna trombofilia. Las trombofilias encontradas fueron: Síndrome Antifosfolípidos, Déficit de Proteína S, Déficit de Proteína C, Déficit de Antitrombina III, Resistencia a la Proteína C – Factor V de Leiden, Hiper factor VIII, Mutación del Gen de la Protrombina 20210A. La mayoría de pacientes presentó eventos trombóticos venosos. El tratamiento más frecuente fue la anticoagulación.